Roche terminates license agreement for AT-527 with Atea; effective Feb 10, 2022

Atea Pharmaceuticals, Inc.

Roche sent termination notice on Nov 12, 2021; license ends Feb 10, 2022.
Agreement covered ex-U.S. rights to develop and commercialize AT-527.
No early termination penalties will be incurred by Atea.
Atea retains full rights to AT-527 outside the terminated pact.

item 1.02

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-331369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.